pCPA Complete its Most Active Month by Adjudicating 15 Files in November

pan-Canadian Pharmaceutical Alliance (pCPA): November 2018 Negotiation Status Update

The pan-Canadian Pharmaceutical Alliance Office (pCPAO) has issued the status of brand negotiations as of November 30, 2018. The key highlights since the October update are:

• 7 new drug products have initiated pCPA negotiations, for a total of 51 active negotiations;
• 9 negotiations were completed for a total of 225 completed negotiations; and
• 2 negotiations were closed since the last update, for a total of 30 closed negotiations.
• The pCPA decided not to negotiate collectively on 4 files, for a total of 58 declined negotiations.

Negotiations Completed/Closed

9 negotiations were completed since the last update, for a total of 225 completed negotiations.

*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation

2 negotiations were closed since the last update, for a total of 30 closed negotiations.

Signals Decoded:

 

In addition to completing three oncology files and the “class negotiation” for the three nitisinone products, pCPA has also concluded discussion on three files that have been in negotiations for well over a year – reaching a deal for Vimizim and closing discussions without agreements for both Copaxone and Cinqair.

Negotiation Initiation

The pCPA has initiated 7 new negotiations since the last update, for a total of 51 active negotiations

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation

Signals Decoded:

 

Of the 4 files initiated in November with final HTA dates after July 2018, only Kanuma was initiated within the pCPA Brand Process Guideline target completion time of ≤ 40 business days. Of note, the pCPA has re-initiated negotiations on Januvia and has initiated discussions on Dupixent, a file that received a positive INESSS recommendation, conditional on improving cost-effectiveness but a “do not reimburse” recommendation from CDEC.

Files Under pCPA Consideration

In addition to the monthly updates to the pCPA website, MORSE Consulting tracks the number of products “under pCPA Consideration” which have been reviewed by CADTH but have not yet been initiated for negotiation or closed without negotiations.

Three new drug products received a CDEC or pERC recommendation or notification to implement in November 2018, for a total of approximately 11 products under pCPA Consideration.

No Negotiations

The pCPA decided not to negotiate 4 files since the last update, for a total of 58 drug products for which the pCPA has decided not to negotiate collectively.

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.